加拿大将肾脏遗传服务纳入慢性肾脏病诊断路径的实施
该前瞻性队列研究纳入2020年3月至2024年3月转诊至肾脏遗传门诊的300名参与者(256个家系),采用基因panel及靶向外显子测序的标准化检测流程。结果显示33%(85/256)的家系检出致病性变异,综合检测使诊断率从基因panel单独检测的23%(70/300)提高至34%(103/300)。从CKD首次诊断至遗传评估的中位时间长达10.4年,而遗传评估后获得阳性结果的中位时间为2.9个月。
要点
- 标准化转诊标准和检测流程可在约三分之一CKD家系中建立遗传诊断。
- 综合检测(基因panel联合靶向外显子测序)较单独基因panel提高诊断率。
- CKD诊断至遗传评估的中位时间长达10.4年,需缩短转诊延迟。
核心结论
- 建立转诊指南和标准化检测算法可在三分之一参与者中建立遗传诊断,为将遗传评估整合入CKD诊断路径提供依据。
研究设计与样本
- 前瞻性队列研究,纳入2020年3月至2024年3月转诊至肾脏遗传门诊的300名参与者(256个家系)。
- 检测策略包括基因panel,若阴性或不适用则进行靶向外显子测序分析。
主要发现
- 在33%(85/256)的家系中检出致病性变异。
- 诊断率从基因panel单独检测的23%(70/300)提高至综合检测的34%(103/300)。
- 从CKD首次诊断至遗传评估的中位时间为10.4年。
- 遗传评估后获得阳性遗传结果的中位时间为2.9个月。
- 接受遗传诊断的患者中记录了多个层面的临床效用,且因CKD亚型而异。
关键数值与推荐
- 使用预设临床转诊标准和诊断流程进行遗传评估。
- 检测针对已知导致CKD的基因中的变异。
临床怎么用
- 在CKD诊断路径中采用预设转诊标准和标准化检测算法可提高遗传诊断率。
- 需制定策略缩短从CKD诊断至遗传评估的时间。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Genetic kidney disease (GKD) accounts for 10% to 20% of chronic kidney disease (CKD). Genetic testing using gene panel or targeted exome sequencing (ES) can confirm GKD; however, integration into clinical practice has been hampered by small studies, selective populations, and data predominately derived from research settings. Using prespecified clinical referral criteria and a diagnostic pipeline, we performed a prospective cohort study describing diagnostic efficacy and clinical utility of genetic assessment in patients with CKD. METHODS: We analyzed a prospective cohort of 300 participants (256 families) referred to a kidney genetics clinic, between March 2020 and March 2024. Testing strategies included gene panels, and if negative or unsuitable, targeted ES analysis. Testing was performed for the detection of variants in genes known to cause CKD. RESULTS: We identified a causative variant in 33% of families (85/256). Diagnostic yield increased from 23% (n = 70/300) from gene panel alone, to 34% (n = 103/300) with comprehensive testing. The median time from first diagnosis of CKD to genetic assessment was long at 10.4 years. Following genetic assessment, the median time to receive a positive genetic result was 2.9 months. Multiple levels of clinical utility were recorded in patients receiving a genetic diagnosis, varying across CKD subtype. CONCLUSION: Instituting referral guidelines and a standardized testing algorithm established a genetic diagnosis in one-third of participants, providing insight into the viability of integrating genetic assessment in the CKD diagnostic pathway. Considering the potential for clinical utility, strategies to reduce the time from CKD diagnosis to genetics assessment are needed.
引用
- Schott C, Arnaldi M, Baker C, et al. Implementation of a Kidney Genetic Service Into the Diagnostic Pathway for Patients With Chronic Kidney Disease in Canada. Kidney Int Rep. 2024. PMID: 39990878. doi:10.1016/j.ekir.2024.11.004
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。